What to Expect Before, During, and After ACP-01 Treatment

One of the biggest barriers between a patient and a treatment decision is not fear of the therapy itself. It is fear of the unknown. What exactly will happen? How many appointments? What does the procedure feel like? What does recovery look like?

This article answers those questions directly, step by step. ACP-01 is investigational, and individual treatment protocols may vary based on your specific condition. But this is how the process works.

Before Treatment: The Evaluation Phase

Nothing happens before a thorough evaluation. The Hemostemix clinical team reviews your medical history, prior imaging, and current condition before any treatment discussion begins.

You will need to provide or authorize access to relevant medical records, including angiography or vascular imaging, prior surgical reports, and current medications. This review typically takes a few days.

If the clinical team determines you may be a candidate, you will have a detailed conversation about the treatment process, realistic expectations, the access pathway, and associated costs. You will be given time to ask questions and to involve your own physician in the decision if you choose.

Informed consent is required before proceeding. Treatment is an out-of-pocket expense because ACP-01 is not approved and is not covered by standard insurance.

The Blood Draw: What Actually Happens

If you proceed, the first step is a simple peripheral blood draw from your arm. This is done as an outpatient office procedure. There is no surgery, no general anesthesia, and no hospital admission required.

The blood is drawn the same way a routine blood test is performed. It typically takes 30 to 60 minutes. You are awake the entire time.

The sample is then sent to a specialized laboratory where the angiogenic cell precursors (ACPs) are isolated and concentrated. This processing step takes several days.

The Delivery: How Cells Are Administered

Once the cells are prepared, they are delivered to the ischemic tissue. For leg artery disease and CLTI, this is typically done through targeted intramuscular injections in the lower leg. For cardiac conditions, delivery is intracoronary or transendocardial, guided by imaging.

The delivery procedure is minimally invasive. Most patients travel for treatment, remain near the treatment centre for approximately seven days, and then return home. Remote follow-up monitoring continues after discharge.

After Treatment: What the Recovery Looks Like

ACP-01 does not produce immediate results. The mechanism of action is biological, not mechanical. The cells need time to release growth factors, stimulate new vessel formation, and allow circulation to improve.

Most clinical data shows measurable changes developing over weeks to months. In the Phase II CLTI trial, wound size reduction from 146 mm² to 0.48 mm² was observed at three months. In cardiac studies, improvements in ejection fraction were seen at two to four months.

Patients are monitored through regular remote follow-up appointments and, where applicable, in-person diagnostic assessments. The clinical team remains in contact throughout.